Company: PRGO
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0001585364-25-000014
Chunk: 44

Company: PERRIGO Co plc
Filing Date: 2025-02-28
Form: 10-K
Item: Item 7
Chunk 44
---
 and lower variable employee costs. These decreases were partially offset by impairment charges of $38.6 million, higher restructuring costs and higher advertising and promotion compared to the prior year, primarily for Opill®.

43

Perrigo Company plc - Item 7CSCI

CONSUMER SELF-CARE INTERNATIONAL

Segment Financial Results

Year Ended(in millions, except percentages)December 31, 2024December 31, 2023Net sales$1,679.6 $1,693.3 Gross profit$763.5 $772.0 Gross profit %45.5 %45.6 %Operating income (loss)$105.0 $(35.2)Operating income %6.3 %(2.1)%

Net sales decreased $13.7 million, or 0.8% primarily due to:

•$50.6 million decrease from the divestiture of the Rare Diseases and Hospital and Specialty Businesses and the sale of branded products; and 

•$10.0 million decrease from unfavorable foreign currency translation; partially offset by

•$46.9 million, or 2.9%, net increase due primarily to approximately $154 million of strategic pricing actions and new products, partially offset by lower net sales across most product categories, primarily Upper Respiratory due to lower cough cold and allergy seasonal demand compared to the prior year. 

CSCI net sales by product category were as follows:

SalesYear Ended(in millions, except percentages)December 31, 2024December 31, 2023 (1)$ Change% ChangeSkin Care$410.0 $372.5 $37.5 10.1 %Upper Respiratory282.1 299.1 (17.0)(5.7)%Healthy Lifestyle225.8 225.7 0.1 — %Pain and Sleep-Aids222.2 222.9 (0.7)(0.4)%VMS173.5 185.5 (12.0)(6.6)%Women's Health132.8 119.7 13.1 11.0 %Oral Care99.4 101.5 (2.1)(2.0)%Digestive Health36.5 41.0 (4.5)(11.0)%Other CSCI97.3 125.4 (28.1)(22.4)%Total CSCI$1,